Market to Grow by 12.1% to Reach $6.97 Billion this Year - Investment Opportunities to 2029
DUBLIN — The 'Canada Diabetes Devices and Therapeutics Market Investment Opportunities – Q2 2025 Update' report has been added to ResearchAndMarkets.com's offering.
Article content
The diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6.97 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6.22 billion to approximately USD 11.37 billion.
Article content
This report provides a detailed data-centric analysis of the diabetes industry in Canada, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.
Article content
The diabetes devices and therapeutics market in Canada comprises established multinational firms and emerging domestic players. A structured healthcare system with defined reimbursement pathways supports traditional and digital solutions. The Canadian diabetes devices and therapeutics market is characterized by a blend of multinational leaders and emerging technology-driven entrants. Recent strategic partnerships, mergers, and acquisitions indicate a move toward more integrated care solutions. In the coming years, competitive dynamics are expected to intensify, driven by consolidation and a focused shift toward digital integration and regulatory compliance.
Article content
The Canadian market is experiencing significant shifts, with increased CGM adoption, digital integration, advanced therapeutic systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures across provincial healthcare systems.
Article content
Expand Continuous Glucose Monitoring Usage
Article content
Canadian healthcare systems are broadening the use of continuous glucose monitoring (CGM) devices across several provinces. Provincial pilot programs in regions such as Ontario and British Columbia are incorporating CGM into routine diabetes care.
Adjustments in provincial reimbursement policies and recent clinical studies from Canadian health agencies support wider CGM use. Recent publications have highlighted a shift in clinical practice toward data-driven patient monitoring.
The adoption of CGM is expected to intensify as more provinces expand coverage and integrate real-time data into care protocols. Enhanced patient monitoring may improve diabetes management outcomes over the medium term.
Article content
Digital health platforms that support remote monitoring and telemedicine are increasingly integrated into diabetes management in Canada. Several regional healthcare systems have initiated digital dashboards to consolidate patient data for clinical decision-making.
Government initiatives to improve telehealth services and recent shifts in healthcare delivery models are driving digital integration. Recent publications underscore provincial health ministries' investments in digital infrastructure.
The integration of digital tools is projected to grow, supporting real-time care adjustments and enhanced data sharing among providers. This trend is expected to intensify as digital health reshapes chronic disease management.
Article content
Advance Therapeutic Delivery Systems
Article content
Advanced therapeutic devices such as smart insulin pens and connected insulin pumps are being tested in clinical settings across Canada. Pilot programs in select provinces have assessed these devices for precise dosing and improved treatment adherence.
Recent technological improvements and research findings from Canadian institutions support the development of these systems. Funding and innovation incentives from provincial health programs are fostering the introduction of these therapeutic tools.
Adoption will likely grow as clinical evidence and reimbursement models evolve, integrating these devices into standard practice. The trend is expected to intensify gradually, influencing treatment protocols in diabetes care.
Article content
Regulatory and Reimbursement Models
Article content
Regulatory bodies in Canada are updating guidelines and reimbursement policies to accommodate new diabetes devices and therapeutics. Recent policy documents have outlined pathways for including digital health and connected devices in public healthcare programs.
Broader cost-containment strategies and ongoing evaluations of digital health effectiveness drive regulatory adjustments. Publications from provincial health ministries and Health Canada provide context for these evolving frameworks.
Clearer regulatory and reimbursement models are anticipated to further support device integration and market expansion. These changes are expected to have a progressive impact, offering more defined channels for innovation in diabetes management.
Article content
Key Competitors and New Entrants
Article content
Several longstanding multinational companies hold significant market share. They offer a range of devices, from continuous monitoring systems to therapeutic delivery tools, and maintain strategic relationships with provincial healthcare agencies.
New market entrants, including technology-focused startups, are introducing digital health solutions that target remote monitoring and data integration. Recent publications indicate that pilot programs in provinces allow these entrants to demonstrate value.
Article content
Recent publications detail partnerships where established companies collaborate with digital health startups to enhance device connectivity and patient data analytics. Mergers and acquisitions have been noted as firms consolidate technical expertise and broaden their market offerings within the Canadian context.
These strategic developments reshape the market by promoting integrated care solutions and streamlined regulatory compliance. Collaborative efforts are aligning product innovation with provincial healthcare priorities.
Article content
Future Competitive Dynamics (2-4 Years)
Article content
The competitive landscape is expected to evolve as strategic partnerships and consolidation efforts deepen. Companies will likely increase investments in digital health integration, balancing established market leaders with nimble entrants.
Over the next 2-4 years, market consolidation and technology-driven innovation are anticipated to further define competitive positioning, with clear implications for patient management strategies.
Article content
Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
Article content
Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
Article content
Self-Monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring Devices
Test Strips
Lancets
Article content
Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
Article content
Insulin Pumps
Insulin Pens
Insulin Syringes
Article content
Diabetes Devices and Therapeutics Market Share by Therapeutics
Article content
Oral Anti-Diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
Article content
Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
Article content
Alpha-Glucosidase Inhibitors
DPP-4 Inhibitors
SGLT-2 Inhibitors
Article content
Diabetes Devices and Therapeutics Market Share by Insulin
Article content
Basal or Long-Acting
Bolus or Fast-Acting
Traditional Human Insulin Drugs
Insulin Biosimilars
Article content
Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
Article content
GLP-1 Receptor Agonists
Amylin Analogue
Article content
Diabetes Devices and Therapeutics Market Share by Combination Drugs
Article content
Combination Insulin
Oral Combination
Article content
Diabetes Devices and Therapeutics Market Share by Route of Administration
Article content
Subcutaneous
Intravenous
Others
Article content
Diabetes Devices and Therapeutics Market Share by Type of Diabetes
Article content
Type 1 Diabetes
Type 2 Diabetes
Article content
Diabetes Devices and Therapeutics Market Share by Distribution Channels
Article content
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Article content
Diabetes Devices and Therapeutics Market Share by End User
Article content
Hospitals
Diabetes Clinics
Homecare
Article content
Key Attributes:
Article content
Report Attribute Details
No. of Pages 50
Forecast Period 2025 – 2029
Estimated Market Value (USD) in 2025 $7.77 Billion
Forecasted Market Value (USD) by 2029 $11.37 Billion
Compound Annual Growth Rate 10.0%
Regions Covered Canada
Article content
For more information about this report visit https://www.researchandmarkets.com/r/5c4fnb About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
23 minutes ago
- Globe and Mail
Trident Resources Announces Disposition of Lincoln Gold Mining Inc. Shares
Vancouver, BC, July 15, 2025 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSX-V: ROCK ) (OTCQB: TRDTF ) ('Trident' or the 'Company') announces the disposition of securities of Lincoln Gold Mining Inc. ("Lincoln") (TSXV: LMG) on the TSX Venture Exchange. On July 14, 2025 and July 15, 2025, Trident disposed of 4,500,000 common shares (the 'Subject Shares') of Lincoln. The Subject Shares represented approximately 19.9% of all issued and outstanding common shares of Lincoln as of July 15, 2025 (22,559,831 per Lincoln's MD&A dated May 30, 2025), immediately following the transaction described above, resulting in a corresponding decrease in the percentage of shares held by Trident as a result of the transaction. Immediately before the transaction described above, Trident held 4,500,000 common shares of Lincoln (the 'Pre-Shares'), representing approximately 19.9% of the issued and outstanding common shares of Lincoln. Immediately following the transaction described above, Trident held 0 common shares of Lincoln (the 'Post-Shares'), representing approximately 0% of the issued and outstanding common shares of Lincoln. The Subject Shares were sold at a price of $0.20 per Subject Share, for an aggregate consideration of $900,000. The holdings of securities of Lincoln by Trident are managed for investment purposes. Trident may from time to time acquire additional securities of Lincoln, dispose of some or all of the existing or additional securities they hold or will hold, or may continue to hold their current positions. A copy of the applicable securities report filed in connection with the matters set forth above may be obtained on SEDAR+ under the profiles of the Company and Lincoln. About Trident Resources Corp.: Trident Resources Corp. is a Canadian public mineral exploration company listed on the TSX Venture Exchange focused on the acquisition, exploration and development of advanced-stage gold and copper exploration projects in Saskatchewan, Canada. The Company is advancing its 100% owned Contact Lake and Greywacke Lake projects which host significant historical gold resources located within the prospective and underexplored La Ronge Gold Belt, as well as the 100% owned Knife Lake copper project which contains a historical copper resource. Trident's Project Portfolio Map: To find out more about Trident Resources Corp. (TSX-V: ROCK), visit the Company's website at Trident Resources Corp. Jonathan Wiesblatt, Chief Executive Officer Email: For further information contact myself or: Andrew J. Ramcharan, PhD, Corporate Communications Trident Resources Corp. Telephone: 647-309-5130 Toll Free: 800-567-8181 Facsimile: 604-687-3119 Email: info@ NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE. Forward-Looking Information and Statements This release includes certain statements that may be deemed to be "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, regulatory approvals, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at for further information. This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Globe and Mail
23 minutes ago
- Globe and Mail
Frontier to Report Second-Quarter 2025 Earnings on July 29, 2025
Frontier Communications Parent, Inc. (NASDAQ:FYBR): What's happening? Frontier Communications Parent, Inc. (NASDAQ: FYBR) ('Frontier') today announced it will report its second-quarter 2025 financial results after the market closes on Tuesday, July 29, 2025. Pending Acquisition by Verizon As previously announced, on September 4, 2024, Verizon Communications Inc. ('Verizon') and Frontier Communications Parent, Inc. entered into a definitive agreement for Verizon to acquire Frontier (the 'transaction'). Due to the pending transaction, Frontier will not host a conference call to review quarterly results or provide a financial outlook. About Frontier Frontier (NASDAQ: FYBR) is the largest pure-play fiber provider in the U.S. Driven by our purpose, Building Gigabit America®, we deliver blazing-fast broadband connectivity that unlocks the potential of millions of consumers and businesses. For more information, visit
Globe and Mail
23 minutes ago
- Globe and Mail
RioCan Real Estate Investment Trust Announces July 2025 Distribution
RioCan Real Estate Investment Trust ('RioCan') (TSX: today announced a distribution of 9.65 cents per unit for the month of July. The distribution will be payable on August 8, 2025, to unitholders of record as at July 31, 2025. About RioCan RioCan is one of Canada's largest real estate investment trusts. RioCan owns, manages and develops retail-focused, mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at March 31, 2025, our portfolio is comprised of 177 properties with an aggregate net leasable area of approximately 32 million square feet (at RioCan's interest). To learn more about us, please visit
